# RhodoLED

Type: Technology

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/rhodoled
Canonical HTML page: https://gethealthbrief.com/entity/rhodoled

## Timeline

- **2026-03-19**: Q4 2025 Earnings — Both companies report year-end results showing strong commercial momentum and narrowing losses.
- **2025-11-10**: Major Health Plan Contract — DarioHealth signs a multi-year agreement with a top-five national US health insurer.
- **2025-07-22**: Biofrontera Supply Chain Update — Resolution of RhodoLED manufacturing bottlenecks, enabling faster lamp deployment.
- **2025-03-15**: DarioHealth MSK Launch — Full integration of musculoskeletal health modules into the core digital platform.

## Recent coverage (1 stories)

### Biofrontera and DarioHealth Q4 Results Signal Shift Toward Commercial Scaling
2026-03-19 17:04:29 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biofrontera and DarioHealth reported Q4 2025 earnings, highlighting a pivotal transition from clinical development to aggressive commercial scaling. While Biofrontera capitalizes on its dermatology market share with Ameluz, DarioHealth is demonstrating the viability of its multi-condition digital health platform through expanded B2B partnerships.
Full story: https://gethealthbrief.com/story/biofrontera-dariohealth-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.